The shadow of generic challenges has repeatedly loomed above copyright’s blockbuster drug, PDE5 Inhibitor, raising questions about the outlook of related pharmaceutical holdings. While first times saw impressive gains, the patent expiration has allowed the path for cheaper alternatives, potentially reducing earnings and posing a genuine hazard fo